Jonah Feldman
Articles
5-Year Survival Data Showcases Long-Term Benefit With Nivolumab/Ipilimumab-Treated Metastatic NSCLC
June 12, 2022
Article
Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.
Investigators Inch Closer to Unlocking CAR T-Cell Therapy Potential in Solid Tumors
April 13, 2022
Article
Findings from a phase 1 trial evaluating CAR T-cell therapy in patients with solid tumors showed promising clinical benefit with the treatment strategy.
More Research Is Needed to Utilize Biomarkers in Endometrial Cancer
January 30, 2022
Article
An expert from the Ohio State University Comprehensive Cancer Center discusses whether predictive biomarkers hold the potential to change endometrial prognoses.